Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R115777 (Tipifarnib) in Relapsed Small Cell Lung Cancer
NCT00005041Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 1999
- Primary completion
- May 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib in small cell lung cancer (SCLC), sponsored by NYU Langone Health. Started Sep 1999; status: completed.
02
Drugs
tipifarnib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00005041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005041.